{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:21:13Z","timestamp":1792783273325,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Charles University Research Program Cooperatio Cardiovascular Science","id":[{"id":"https:\/\/ror.org\/024d6js02","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"DOI":"10.1007\/s11886-026-02423-y","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:58:33Z","timestamp":1791007113000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Eosinophilia and the Heart: Evolving Concepts"],"prefix":"10.1007","volume":"28","author":[{"given":"Jan","family":"Habasko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Kuchynka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayara Elisa","family":"Bonatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Palecek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"issue":"5","key":"2423_CR1","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/ajh.27287","volume":"99","author":"W Shomali","year":"2024","unstructured":"Shomali W, Gotlib J. World Health Organization and International Consensus classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024;99(5):946\u201368.","journal-title":"Am J Hematol"},{"key":"2423_CR2","doi-asserted-by":"publisher","unstructured":"Kuchynka P, Brucato A, Tsch\u00f6pe C, Cameli M, Castelletti S, Cooper LT, et al. Current state of knowledge on the epidemiology, aetiology, diagnosis, and management of heart involvement in eosinophilia. A Clinical Consensus Statement of the ESC Working Group on Myocardial & Pericardial Diseases. Eur J Heart Fail. 2026;xuag043. https:\/\/doi.org\/10.1093\/ejhf\/xuag043.","DOI":"10.1093\/ejhf\/xuag043"},{"issue":"9","key":"2423_CR3","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.125.074797","volume":"153","author":"E Ammirati","year":"2026","unstructured":"Ammirati E, Palazzini M, Lehtonen J, Potena L, M\u00e4yr\u00e4np\u00e4\u00e4 MI, R\u00e5gback J, et al. Natural history of patients with histologically proven acute eosinophilic myocarditis. Circulation. 2026;153(9):634\u201352.","journal-title":"Circulation"},{"key":"2423_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvag025","author":"AS Giordani","year":"2026","unstructured":"Giordani AS, Menghi C, Baritussio A, Scognamiglio F, Vicenzetto C, Davanzo F, et al. Monoclonal antibodies targeting IL-5\/5R or IL-4\/13 pathways in eosinophilic myocarditis: a single-centre experience and systematic literature review. Eur Heart J Cardiovasc Pharmacother. 2026. https:\/\/doi.org\/10.1093\/ehjcvp\/pvag025.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"3","key":"2423_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jacc.2019.04.063","volume":"74","author":"E Ammirati","year":"2019","unstructured":"Ammirati E, Veronese G, Brambatti M, et al. Fulminant versus acute nonfulminant myocarditis in patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2019;74(3):299\u2013311.","journal-title":"J Am Coll Cardiol"},{"key":"2423_CR6","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1161\/CIRCULATIONAHA.121.058869","volume":"146","author":"K Kanaoka","year":"2022","unstructured":"Kanaoka K, Onoue K, Terasaki S, et al. Features and outcomes of histologically proven myocarditis with fulminant presentation. Circulation. 2022;146:1425\u201333.","journal-title":"Circulation"},{"issue":"19","key":"2423_CR7","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1016\/j.jacc.2017.09.023","volume":"70","author":"M Brambatti","year":"2017","unstructured":"Brambatti M, Matassini MV, Adler ED, Klingel K, Camici PG, Ammirati E. Eosinophilic myocarditis: characteristics, treatment, and outcomes. J Am Coll Cardiol. 2017;70(19):2363\u201375.","journal-title":"J Am Coll Cardiol"},{"key":"2423_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2829583","author":"P Kuchynka","year":"2016","unstructured":"Kuchynka P, Palecek T, Masek M, et al. Current diagnostic and therapeutic aspects of eosinophilic myocarditis. Biomed Res Int. 2016. https:\/\/doi.org\/10.1155\/2016\/2829583.","journal-title":"Biomed Res Int"},{"issue":"10","key":"2423_CR9","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1136\/heartjnl-2023-323225","volume":"110","author":"W Techasatian","year":"2024","unstructured":"Techasatian W, Gozun M, Vo K, et al. Eosinophilic myocarditis: systematic review. Heart. 2024;110(10):687\u201393.","journal-title":"Heart"},{"key":"2423_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/all.15544","volume":"78","author":"P Valent","year":"2023","unstructured":"Valent P, Klion AD, Roufosse F, et al. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes. Allergy. 2023;78:47\u201359.","journal-title":"Allergy"},{"key":"2423_CR11","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1002\/ajh.26966","volume":"98","author":"SA Wang","year":"2023","unstructured":"Wang SA, Orazi A, Gotlib J, et al. The international consensus classification of eosinophilic disorders and systemic mastocytosis. Am J Hematol. 2023;98:1286\u2013306.","journal-title":"Am J Hematol"},{"key":"2423_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12030656","volume":"12","author":"F Piccirillo","year":"2024","unstructured":"Piccirillo F, Mastroberardino S, Nafisio V, et al. Eosinophilic myocarditis: from bench to bedside. Biomedicines. 2024;12:656.","journal-title":"Biomedicines"},{"key":"2423_CR13","doi-asserted-by":"publisher","first-page":"100118","DOI":"10.1016\/j.jtauto.2021.100118","volume":"4","author":"Z Zhong","year":"2021","unstructured":"Zhong Z, Yang Z, Peng Y, et al. Diagnosis and treatment of eosinophilic myocarditis. J Transl Autoimmun. 2021;4:100118.","journal-title":"J Transl Autoimmun"},{"key":"2423_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.mucimm.2026.100347","author":"JI King","year":"2026","unstructured":"King JI, Arnold IC. Cytokine networks driving eosinophil functional heterogeneity. Mucosal Immunol. 2026;19(4). https:\/\/doi.org\/10.1016\/j.mucimm.2026.100347.","journal-title":"Mucosal Immunol"},{"issue":"18","key":"2423_CR15","doi-asserted-by":"publisher","first-page":"5996","DOI":"10.3390\/jcm12185996","volume":"12","author":"R Watanabe","year":"2023","unstructured":"Watanabe R, Hashimoto M. Eosinophilic granulomatosis with polyangiitis: latest findings and updated treatment recommendations. J Clin Med. 2023;12(18):5996.","journal-title":"J Clin Med"},{"issue":"5","key":"2423_CR16","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.jaci.2025.11.011","volume":"157","author":"CD Nazaroff","year":"2026","unstructured":"Nazaroff CD, Kienzl M, Schutte CA, et al. IRF1 is an upstream regulatory transcription factor of eosinophils in type 1 environments. J Allergy Clin Immunol. 2026;157(5):1162\u201378.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2423_CR17","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1038\/s41467-019-12515-9","volume":"10","author":"PA Lyons","year":"2019","unstructured":"Lyons PA, Peters JE, Alberici F, et al. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nat Commun. 2019;10(1):5120.","journal-title":"Nat Commun"},{"issue":"2","key":"2423_CR18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/heartjnl-2015-307959","volume":"102","author":"R Mankad","year":"2016","unstructured":"Mankad R, Bonnichsen C, Mankad S. Hypereosinophilic syndrome: cardiac diagnosis and management. Heart. 2016;102(2):100\u20136.","journal-title":"Heart"},{"issue":"1","key":"2423_CR19","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13023-023-02696-4","volume":"18","author":"M Groh","year":"2023","unstructured":"Groh M, Rohmer J, Etienne N, et al. French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes. Orphanet J Rare Dis. 2023;18(1):100.","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"2423_CR20","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.echo.2020.09.002","volume":"33","author":"MV Polito","year":"2020","unstructured":"Polito MV, Hagendorff A, Citro R, et al. Loeffler\u2019s endocarditis: an integrated multimodality approach. J Am Soc Echocardiogr. 2020;33(12):1427\u201341.","journal-title":"J Am Soc Echocardiogr"},{"key":"2423_CR21","doi-asserted-by":"publisher","first-page":"1818565","DOI":"10.3389\/fcvm.2026.1818565","volume":"13","author":"AS Giordani","year":"2026","unstructured":"Giordani AS, Menghi C, Baritussio A, et al. Eosinophilic myocarditis: diagnostic pitfalls and therapeutic challenges. A case series. Front Cardiovasc Med. 2026;13:1818565.","journal-title":"Front Cardiovasc Med"},{"issue":"9","key":"2423_CR22","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s10554-016-0917-x","volume":"32","author":"T Yamamoto","year":"2016","unstructured":"Yamamoto T, Tanaka H, Kurimoto C, Imanishi T, Hayashi N, Saegusa J, et al. Very early stage left ventricular endocardial dysfunction of patients with hypereosinophilic syndrome. Int J Cardiovasc Imaging. 2016;32(9):1357\u201361.","journal-title":"Int J Cardiovasc Imaging"},{"issue":"6","key":"2423_CR23","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.21037\/cdt-2025-287","volume":"15","author":"Y Okushi","year":"2025","unstructured":"Okushi Y, Reeder M, Al Zein M, et al. The value of left ventricular and left atrial strains in eosinophilic myocarditis and hypereosinophilic syndrome. Cardiovasc Diagn Ther. 2025;15(6):1122\u201333.","journal-title":"Cardiovasc Diagn Ther"},{"issue":"1","key":"2423_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12968-023-00979-0","volume":"25","author":"P P\u00f6yh\u00f6nen","year":"2023","unstructured":"P\u00f6yh\u00f6nen P, R\u00e5gback J, M\u00e4yr\u00e4np\u00e4\u00e4 MI, et al. Cardiac magnetic resonance in histologically proven eosinophilic myocarditis. J Cardiovasc Magn Reson. 2023;25(1):79.","journal-title":"J Cardiovasc Magn Reson"},{"issue":"11","key":"2423_CR25","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1093\/ehjci\/jeaa346","volume":"22","author":"AS Antonopoulos","year":"2021","unstructured":"Antonopoulos AS, Azzu A, Androulakis E, et al. Eosinophilic heart disease: diagnostic and prognostic assessment by cardiac magnetic resonance. Eur Heart J Cardiovasc Imaging. 2021;22(11):1273\u201384.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"37","key":"2423_CR26","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627\u201339.","journal-title":"Eur Heart J"},{"issue":"40","key":"2423_CR27","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","volume":"43","author":"K Zeppenfeld","year":"2022","unstructured":"Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997\u20134126.","journal-title":"Eur Heart J"},{"issue":"13","key":"2423_CR28","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1001\/jama.2023.3371","volume":"329","author":"E Ammirati","year":"2023","unstructured":"Ammirati E, Moslehi JJ. Diagnosis and treatment of acute myocarditis: a review. JAMA. 2023;329(13):1098\u2013113.","journal-title":"JAMA"},{"issue":"6","key":"2423_CR29","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v17.i6.107729","volume":"17","author":"TV Luong","year":"2025","unstructured":"Luong TV, Hoang TA, Pham NN, et al. Eosinophilic myocarditis due to parasitic infection: a case-based minireview. World J Cardiol. 2025;17(6):107729.","journal-title":"World J Cardiol"},{"key":"2423_CR30","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.1182\/blood-2009-07-143552","volume":"114","author":"AD Klion","year":"2009","unstructured":"Klion AD. How I treat hypereosinophilic syndromes. Blood. 2009;114:3736\u201341.","journal-title":"Blood"},{"key":"2423_CR31","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1182\/blood-2002-10-3103","volume":"101","author":"A Pardanani","year":"2003","unstructured":"Pardanani A, Reeder T, Porrata LF, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 2003;101:3391\u20137.","journal-title":"Blood"},{"issue":"6","key":"2423_CR32","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41584-023-00958-w","volume":"19","author":"G Emmi","year":"2023","unstructured":"Emmi G, Bettiol A, Gelain E, Bajema IM, Berti A, Burns S, et al. Evidence-based guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol. 2023;19(6):378\u201393.","journal-title":"Nat Rev Rheumatol"},{"key":"2423_CR33","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/art.41773","volume":"73","author":"SA Chung","year":"2021","unstructured":"Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2021;73:1366\u201383.","journal-title":"Arthritis Rheumatol"},{"key":"2423_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1587158","volume":"16","author":"M Lazzeroni","year":"2025","unstructured":"Lazzeroni M, Longoni V, Schiavo P, et al. Anti-IL-5\/IL-5 receptor therapies for eosinophilic granulomatosis with polyangiitis: an updated systematic review. Front Immunol. 2025;16:1587158.","journal-title":"Front Immunol"},{"issue":"1","key":"2423_CR35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11886-024-02184-6","volume":"27","author":"AM Asada","year":"2025","unstructured":"Asada AM, Kahwash R, Trovato V. Eosinophilic myocarditis: a concise review. Curr Cardiol Rep. 2025;27(1):38.","journal-title":"Curr Cardiol Rep"},{"issue":"12","key":"2423_CR36","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa070812","volume":"358","author":"ME Rothenberg","year":"2008","unstructured":"Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008;358(12):1215\u201328.","journal-title":"N Engl J Med"},{"key":"2423_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04315-8","author":"PU Ogbogu","year":"2026","unstructured":"Ogbogu PU, Roufosse F, Akuthota P, et al. Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. Nat Med. 2026;32(6):2017\u201325. https:\/\/doi.org\/10.1038\/s41591-026-04315-8.","journal-title":"Nat Med"},{"issue":"20","key":"2423_CR38","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"ME Wechsler","year":"2017","unstructured":"Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376(20):1921\u201332.","journal-title":"N Engl J Med"},{"issue":"10","key":"2423_CR39","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa2311155","volume":"390","author":"ME Wechsler","year":"2024","unstructured":"Wechsler ME, Nair P, Terrier B, et al. Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2024;390(10):911\u201321.","journal-title":"N Engl J Med"},{"key":"2423_CR40","doi-asserted-by":"crossref","unstructured":"Schultz HM, Valdes D, Butendieck RR Jr, et al. Benralizumab in a patient with refractory eosinophilic endocarditis. J Med Cases. 2025;16(8):271\u20136.","DOI":"10.14740\/jmc5168"},{"issue":"1","key":"2423_CR41","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/mrcr\/rxab022","volume":"6","author":"K Higashitani","year":"2022","unstructured":"Higashitani K, Yoshimi R, Sato Y, et al. Rituximab and mepolizumab combination therapy for glucocorticoid-resistant myocarditis related to eosinophilic granulomatosis with polyangiitis. Mod Rheumatol Case Rep. 2022;6(1):87\u201392.","journal-title":"Mod Rheumatol Case Rep"},{"key":"2423_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1079034","volume":"13","author":"C Lazzari","year":"2023","unstructured":"Lazzari C, Yacoub MR, Campochiaro C, et al. Case report: successful use of mepolizumab for immune checkpoint inhibitors-induced hypereosinophilic syndrome in two patients with solid malignancies. Front Oncol. 2023;13:1079034.","journal-title":"Front Oncol"},{"key":"2423_CR43","first-page":"101763","volume":"40","author":"O Matsuno","year":"2022","unstructured":"Matsuno O, Minamoto S. Benralizumab monotherapy was insufficient to induce remission in patients with active eosinophilic granulomatosis with polyangiitis. Respir Med Case Rep. 2022;40:101763.","journal-title":"Respir Med Case Rep"},{"issue":"11","key":"2423_CR44","doi-asserted-by":"publisher","first-page":"9563","DOI":"10.3390\/ijms24119563","volume":"24","author":"G Scioscia","year":"2023","unstructured":"Scioscia G, et al. Switching biological therapies in severe asthma. Int J Mol Sci. 2023;24(11):9563.","journal-title":"Int J Mol Sci"},{"key":"2423_CR45","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.rmed.2016.01.003","volume":"111","author":"TH Pham","year":"2016","unstructured":"Pham TH, et al. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med. 2016;111:21\u20139.","journal-title":"Respir Med"},{"issue":"6","key":"2423_CR46","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","volume":"125","author":"R Kolbeck","year":"2010","unstructured":"Kolbeck R, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125(6):1344\u201353.","journal-title":"J Allergy Clin Immunol"},{"issue":"19","key":"2423_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14196829","volume":"14","author":"H Takahashi","year":"2025","unstructured":"Takahashi H, Awaya T, Nagamatsu H, et al. Eosinophilic myocarditis treated with IL-5 blockade: an integrated case report and literature review. J Clin Med. 2025;14(19):6829.","journal-title":"J Clin Med"},{"issue":"7","key":"2423_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccas.2024.102267","volume":"29","author":"V Trovato","year":"2024","unstructured":"Trovato V, Asada A, Fussner L, et al. Interleukin-5 antagonist monoclonal antibody therapy improves symptoms and reduces steroid dependence in eosinophilic myocarditis patients. JACC Case Rep. 2024;29(7):102267.","journal-title":"JACC Case Rep"},{"issue":"5","key":"2423_CR49","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/ejhf.3220","volume":"26","author":"ALP Caforio","year":"2024","unstructured":"Caforio ALP, Giordani AS, Baritussio A, et al. Long-term efficacy and safety of tailored immunosuppressive therapy in immune-mediated biopsy-proven myocarditis: a propensity-weighted study. Eur J Heart Fail. 2024;26(5):1175\u201385.","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"2423_CR50","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1080\/17476348.2022.2090342","volume":"16","author":"M Caminati","year":"2022","unstructured":"Caminati M, Olivieri B, Dama A, et al. Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management. Expert Rev Respir Med. 2022;16(7):713\u201321.","journal-title":"Expert Rev Respir Med"},{"issue":"1","key":"2423_CR51","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s10875-025-01914-x","volume":"45","author":"J Wu","year":"2025","unstructured":"Wu J, Li L, Ten W, et al. Dupilumab-induced Eosinophilic Granulomatosis with Polyangiitis Complicated by Peripheral Neuropathic Pain: a Case Report and Literature Review. J Clin Immunol. 2025;45(1):114.","journal-title":"J Clin Immunol"},{"issue":"1","key":"2423_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/allergies6010010","volume":"6","author":"G Laterra","year":"2026","unstructured":"Laterra G, Indaco FG, Bongiorno S, et al. Cardiovascular safety of dupilumab: current evidence and emerging concerns. Allergies. 2026;6(1):10.","journal-title":"Allergies"},{"key":"2423_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccas.2026.108880","author":"I Agredano","year":"2026","unstructured":"Agredano I, Michiels V, Argacha JF, et al. Eosinophilic cardiomyopathy in eosinophilic granulomatosis with polyangiitis after dupilumab therapy. JACC Case Rep. 2026;31(33). https:\/\/doi.org\/10.1016\/j.jaccas.2026.108880.","journal-title":"JACC Case Rep"},{"key":"2423_CR54","unstructured":"A trial to investigate benralizumab in children with eosinophilic diseases (CLIPS). ClinicalTrials.gov identifier: NCT06512883. https:\/\/www.clinicaltrials.gov\/study\/NCT06512883.\u00a0 Accessed 20 Jun 2026."},{"key":"2423_CR55","unstructured":"Study in pediatrics with hypereosinophilic syndrome (SPHERE). ClinicalTrials.gov identifier: NCT04965636. https:\/\/clinicaltrials.gov\/study\/NCT04965636. Accessed 20 Jun 2026."},{"key":"2423_CR56","unstructured":"Depemokimab in participants with hypereosinophilic syndrome, efficacy, and safety trial (DESTINY). ClinicalTrials.gov identifier: NCT05334368. https:\/\/clinicaltrials.gov\/study\/NCT05334368. Accessed 20 Jun 2026."},{"key":"2423_CR57","unstructured":"Efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA) (OCEAN). ClinicalTrials.gov identifier: NCT05263934. https:\/\/clinicaltrials.gov\/study\/NCT05263934. Accessed 20 Jun 2026."},{"key":"2423_CR58","unstructured":"Dupilumab as add -on therapy for hypereosinophilic syndrome with partial clinical response to eosinophil-depleting biologic agents. ClinicalTrials.gov identifier: NCT06477653. https:\/\/clinicaltrials.gov\/study\/NCT06477653. Accessed 20 Jun 2026."},{"key":"2423_CR59","unstructured":"Ruxolitinib in treating patients with hypereosinophilic syndrome or primary eosinophilic disorder. ClinicalTrials.gov identifier: NCT03801434. https:\/\/clinicaltrials.gov\/study\/NCT03801434. Accessed 20 Jun 2026."},{"key":"2423_CR60","unstructured":"Explore the efficacy and mechanism of action of tezepelumab in eosinophilic granulomatosis with polyangiitis (RACEMATE). ClinicalTrials.gov identifier: NCT06230354. https:\/\/clinicaltrials.gov\/study\/NCT06230354. Accessed 20 Jun 2026."},{"issue":"1","key":"2423_CR61","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41577-022-00735-y","volume":"23","author":"R Ebina-Shibuya","year":"2023","unstructured":"Ebina-Shibuya R, Leonard WJ. Role of thymic stromal lymphopoietin in allergy and beyond. Nat Rev Immunol. 2023;23(1):24\u201337.","journal-title":"Nat Rev Immunol"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02423-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-026-02423-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02423-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:58:35Z","timestamp":1791007115000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-026-02423-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2423"],"URL":"https:\/\/doi.org\/10.1007\/s11886-026-02423-y","relation":{},"ISSN":["1534-3170"],"issn-type":[{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"13 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":1,"name":"Ethics","label":"Human and Animal Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Artificial Intelligence was not used for creating of our manuscript.","order":2,"name":"Ethics","label":"Use of Artificial Intelligence","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"103"}}